Focus: Hikma is a specialty pharmaceutical company headquartered in Berkeley Heights, NJ, focused on medication delivery across oncology, infectious diseases, cardiovascular, neurology, and immunology. The company operates primarily in generic and branded specialty pharmaceuticals with a diversified portfolio.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Hikma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product representing 30% of revenue but in mature generic market with ongoing competitive pressure and pricing erosion.
Help build intelligence for Hikma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Hikma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue driver in stable post-LOE position with established patient base in autoimmune indications.
Oncology-focused asset generating meaningful revenue in competitive prostate cancer market with biosimilar positioning.
Only branded NDA product in portfolio with extended exclusivity through 2033, representing differentiation and pricing power potential.
CNS specialty product approaching loss of exclusivity with limited revenue runway, requiring pipeline replacement.
402 discontinued, 268 duplicate formulations not shown
+10 more products with revenue data
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub
Six active drug shortages (Midazolam, Cefotaxime, Morphine, Furosemide, Dopamine) indicate potential manufacturing or supply chain stress that could trigger operational restructuring.
+232 more products